Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on January 27, 2020, covering events occurring on January 27 and January 28, 2020. The Company is incorporated in Delaware and its Class A Common Stock trades on the New York Stock Exchange under the symbol EVH.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Departure: Matt Hobart resigned as a director of the Company on January 27, 2020.
- Director Election and Appointment: On January 28, 2020, the Board elected Peter Grua as a Class I director and appointed him to the Audit Committee.
- Independence: The Board determined Mr. Grua is an independent director in accordance with NYSE and SEC rules.
Management Commentary and Background
Mr. Grua is a Managing Partner at HLM Venture Partners, focusing on health services and medical technologies. His prior experience includes serving as a Managing Director at Alex Brown & Sons and as a director at The Advisory Board Company and Welltower Inc. He currently serves on the boards of several other healthcare-related entities. Mr. Grua will receive standard director indemnification and is eligible for compensation arrangements established for non-employee directors. No special arrangements or understandings influenced his selection.
Investor Verification Checklist
- Verify the effective date of Matt Hobart's resignation and any potential impact on board composition.
- Confirm Peter Grua's independence status and specific qualifications for the Audit Committee role.
- Review the Company's proxy statement or subsequent filings for details on the compensation package for non-employee directors.
- Check for any related party transactions involving Mr. Grua's other board affiliations that may arise in future filings.